The Advisory Council on the Misuse of Drugs (ACMD) said the substance, also known as NRG-1, and analogues should be controlled as a Class B drug.
It follows the high-profile banning of mephedrone in April this year.
In its report, the ACMD said the drug was likely to have similar harmful effects to previously controlled cathinones, such as mephedrone.
The council warned users of the dangers of purchasing compounds which may not contain the material advertised but which may be more harmful and illegal.
Council chairman Professor Les Iversen said: ‘Differences in potency between the apparently identical products could give rise to risk of overdose or unexpected health effects.’
He said the public health response should ‘focus on the discrepancy between the compounds that are purported to be contained in the "legal high" for sale and what the customer actually gets’.
The ACMD also expressed concerns about the proliferation of so-called ‘legal highs’, and said it would give the topic a higher priority in future.